BRPI0706481A2 - anticorpo ou seu fragmento de ligação a antìgeno, anticorpo humanizado, fragmento de ligação a antìgeno, célula hospedeira recombinante transformada ou transfectada, métodos para produzir um anticorpo, para tratar um paciente humano afligido por uma doença, para prevenir ataques asmáticos agudos em um paciente humano, e para reduzir a frequência e/ou mitigar os efeitos dos ataques asmáticos agudos em um paciente humano, composição farmacêutica, kit de partes, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno - Google Patents

anticorpo ou seu fragmento de ligação a antìgeno, anticorpo humanizado, fragmento de ligação a antìgeno, célula hospedeira recombinante transformada ou transfectada, métodos para produzir um anticorpo, para tratar um paciente humano afligido por uma doença, para prevenir ataques asmáticos agudos em um paciente humano, e para reduzir a frequência e/ou mitigar os efeitos dos ataques asmáticos agudos em um paciente humano, composição farmacêutica, kit de partes, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno Download PDF

Info

Publication number
BRPI0706481A2
BRPI0706481A2 BRPI0706481-0A BRPI0706481A BRPI0706481A2 BR PI0706481 A2 BRPI0706481 A2 BR PI0706481A2 BR PI0706481 A BRPI0706481 A BR PI0706481A BR PI0706481 A2 BRPI0706481 A2 BR PI0706481A2
Authority
BR
Brazil
Prior art keywords
antibody
asthma
seq
human
antigen
Prior art date
Application number
BRPI0706481-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Claire Ashman
Martin John Cassidy
Jane Elizabeth Clarkson
Jonathan Henry Ellis
Trevor Anthony Kenneth Wattam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0706481(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0706481A2 publication Critical patent/BRPI0706481A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0706481-0A 2006-01-11 2007-01-10 anticorpo ou seu fragmento de ligação a antìgeno, anticorpo humanizado, fragmento de ligação a antìgeno, célula hospedeira recombinante transformada ou transfectada, métodos para produzir um anticorpo, para tratar um paciente humano afligido por uma doença, para prevenir ataques asmáticos agudos em um paciente humano, e para reduzir a frequência e/ou mitigar os efeitos dos ataques asmáticos agudos em um paciente humano, composição farmacêutica, kit de partes, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno BRPI0706481A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0600488.1 2006-01-11
GBGB0600488.1A GB0600488D0 (en) 2006-01-11 2006-01-11 Immunoglobulins
PCT/EP2007/050219 WO2007080174A2 (en) 2006-01-11 2007-01-10 Chimeric and humanised anti-human il-13 antibodies

Publications (1)

Publication Number Publication Date
BRPI0706481A2 true BRPI0706481A2 (pt) 2011-03-29

Family

ID=35997844

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706481-0A BRPI0706481A2 (pt) 2006-01-11 2007-01-10 anticorpo ou seu fragmento de ligação a antìgeno, anticorpo humanizado, fragmento de ligação a antìgeno, célula hospedeira recombinante transformada ou transfectada, métodos para produzir um anticorpo, para tratar um paciente humano afligido por uma doença, para prevenir ataques asmáticos agudos em um paciente humano, e para reduzir a frequência e/ou mitigar os efeitos dos ataques asmáticos agudos em um paciente humano, composição farmacêutica, kit de partes, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno

Country Status (18)

Country Link
EP (1) EP1976881A2 (es)
JP (1) JP2009523154A (es)
KR (1) KR20080113201A (es)
CN (1) CN101370829A (es)
AR (1) AR058955A1 (es)
AU (1) AU2007204372A1 (es)
BR (1) BRPI0706481A2 (es)
CA (1) CA2635972A1 (es)
CR (1) CR10161A (es)
EA (1) EA200801520A1 (es)
GB (1) GB0600488D0 (es)
IL (1) IL192207A0 (es)
MA (1) MA30156B1 (es)
NO (1) NO20082767L (es)
PE (1) PE20081185A1 (es)
TW (1) TW200736274A (es)
WO (1) WO2007080174A2 (es)
ZA (1) ZA200805526B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
AU2007267213B2 (en) 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP2012509658A (ja) * 2008-11-26 2012-04-26 グラクソ グループ リミテッド Ｉｌ−１３に結合するリガンド
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
KR20120034679A (ko) * 2009-05-28 2012-04-12 글락소 그룹 리미티드 Ｉｌ-13 결합 단백질
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
CN103328506A (zh) * 2010-10-15 2013-09-25 米迪缪尼有限公司 用于改善肺功能的疗法
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
UA117608C2 (uk) 2014-02-21 2018-08-27 Дженентек, Інк. Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
US10066267B2 (en) 2014-04-11 2018-09-04 Novartis Ag Methods of selectively treating asthma using IL-13 antagonists
AU2016233398A1 (en) 2015-03-16 2017-09-07 F. Hoffmann-La Roche Ag Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
JPWO2018135653A1 (ja) * 2017-01-23 2020-01-09 学校法人 東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
CN109776677B (zh) * 2017-11-15 2023-11-03 尚华科创投资管理（江苏）有限公司 一种人源化抗il-13抗体及其制备方法和应用
CN107909501B (zh) * 2017-12-05 2020-12-01 创新先进技术有限公司 气味与行为的关联方法、气味社交方法及装置
KR20230142806A (ko) 2018-02-09 2023-10-11 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2020191293A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
CN119638833A (zh) * 2024-12-19 2025-03-18 江苏荃信生物医药股份有限公司 一种人il-13抗体、elisa试剂盒及其检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496607A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccine comprising il-13 and an adjuvant
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
JP4943161B2 (ja) * 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
AR058955A1 (es) 2008-03-05
KR20080113201A (ko) 2008-12-29
IL192207A0 (en) 2008-12-29
CR10161A (es) 2008-11-26
EP1976881A2 (en) 2008-10-08
PE20081185A1 (es) 2008-10-07
WO2007080174A3 (en) 2007-12-06
NO20082767L (no) 2008-10-06
CN101370829A (zh) 2009-02-18
EA200801520A1 (ru) 2009-02-27
GB0600488D0 (en) 2006-02-22
WO2007080174A2 (en) 2007-07-19
CA2635972A1 (en) 2007-07-19
AU2007204372A1 (en) 2007-07-19
ZA200805526B (en) 2009-10-28
MA30156B1 (fr) 2009-01-02
JP2009523154A (ja) 2009-06-18
TW200736274A (en) 2007-10-01

Similar Documents

Publication Publication Date Title
ES2456897T3 (es) Anticuerpos monoclonales quiméricos y humanizados contra la interleuquina 13
CA2635972A1 (en) Chimeric and humanised anti-human il-13 antibodies
CN112513090B (zh) 结合人il-4r的抗体、其抗原结合片段及其医药用途
US8323646B2 (en) Engineered anti-IL-13 antibodies, compositions, methods and uses
AU2016239858A1 (en) Antibodies to canine interleukin-4 receptor alpha
MXPA06014564A (es) Anticuerpos que se unen a il13.
CN105026426A (zh) 血小板衍生生长因子b之特异性抗体及其组合物和用途
CN102993302A (zh) 新的抗il-13抗体及其应用
BR112013009083B1 (pt) Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada
BR112019025048A2 (pt) anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos
WO2019120060A1 (zh) 结合人il-5的单克隆抗体、其制备方法和用途
BR112019012929A2 (pt) anticorpos anti-il-5
BR112020005766A2 (pt) anticorpo il-5, fragmento de ligação ao antígeno do mesmo, e aplicação médica do mesmo
CN101039960B (zh) 抗il-13的嵌合人源化单克隆抗体
MX2008008946A (es) Anticuerpos anti-il-13 (interleucina 13) humana quimericos y humanizados
HK1163123A (en) Chimeric and humanised monoclonal antibodies against interleukin-13
BR122025002522A2 (pt) Anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica e uso da mesma
BR122024026201A2 (pt) Anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica e uso da mesma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2218 DE 09/07/2013.